28,490 resources
By Version
By Authority
By Realm
Start Prev Rows 1200 - 1400 Next
Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Realm | Auth | Source(s) |
---|---|---|---|---|---|---|---|---|---|---|
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1074 | Hemifacial spasm I10 | active | 2025-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1075 | Hemifacial spasm | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1076 | Spasmodic dysphonia SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1077 | Physical therapy procedure SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1078 | Occupational therapy SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1079 | Hyperhidrosis SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1080 | Hyperhidrosis I10 | active | 2025-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1081 | Hyperhidrosis | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1082 | Tic disorder I10 | active | 2025-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1083 | Tic disorder SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1084 | Tic disorder | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1085 | Esophageal achalasia SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1086 | Esophageal achalasia I10 | active | 2025-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1087 | Esophageal achalasia | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1088 | ET propanolol or primidone | active | 2025-05 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1089 | ET topiramate alprazolam or gabapentin | active | 2025-05 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.109 | CKD stage4above I10 | active | 2024-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1090 | Blephraospasm SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1091 | Blepharospasm I10 | active | 2025-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1092 | Blepharospasm | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1093 | Strabismus SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1094 | Strabismus I10 | active | 2025-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1095 | Strabismus | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1096 | Overactive bladder SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1097 | Overactive bladder I10 | active | 2025-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1098 | Overactive bladder | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1099 | Movement disorders SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.110 | CKD stage4above SCT | active | 2024-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1100 | Movement disorders I10 | active | 2025-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1101 | Movement disorders | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1102 | Lateral epicondylitis SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1103 | Lateral epicondyltisis I10 | active | 2025-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1104 | Lateral epicondylitis | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1105 | Plantar fasciitis SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1106 | Plantar fasciitis I10 | active | 2025-05 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1107 | Plantar fasciitits | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1108 | Cardiac CT SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1109 | Cardiac CT CPT | active | 2025-05 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.111 | CKD stage4above | active | 2024-06 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1111 | Cardiac CT | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1112 | Cardiac MRI SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1113 | Cardiac MRI CPT | active | 2025-05 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1114 | Cardiac MRI | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1115 | CT Angiography of Coronary Artery SCT | active | 2025-05 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1116 | CT Angiography of Coronary Artery CPT | active | 2025-05 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.1117 | CT Angiography of Coronary Artery | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.120 | Diabetic ketoacidosis SCT | active | 2023-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.121 | Diabetic ketoacidosis | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.146 | Long Acting Muscarinic Antagonists (LAMA) | active | 2023-11 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.159 | conditions_COPD I10 | active | 2024-08 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.175 | Asthma | active | 2025-05 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.184 | DigTx Virtual Reality Contraindications Visual Impairment | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.186 | Beta blockers GDMT for heart failure | active | 2023-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.188 | medications_heart failure | active | 2024-12 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.197 | Blood (Serum and Plasma) Potassium | active | 2023-11 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.214 | Type 1 Diabetes Mellitus SCT | active | 2023-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.238 | MRA mineralocorticoid receptor antagonists | active | 2024-10 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.244 | MRA Mineralocorticoid Receptor Antagonist Allergy | active | 2023-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.260 | UACR SCT | active | 2023-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.263 | Pregnancy I10 | active | 2023-11 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.281 | Statins Allergy SCT | active | 2023-03 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.282 | Statin Allergy Intolerance | active | 2025-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.314 | relatedconditions_hyperlipidemia I10 | active | 2023-10 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.337 | Migraine I10 | active | 2023-03 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.34 | Blood pressure panel | active | 2024-04 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.35 | Systolic Blood Pressure | active | 2024-04 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.367 | Trandolapril | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.369 | Candesartan | active | 2023-07 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.377 | Valsartan | active | 2023-07 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.397 | eGFR | active | 2025-03 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.412 | Statin Moderate Intensity | active | 2024-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.415 | LDL Cholesterol | active | 2024-02 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.43 | Urinalysis | active | 2024-02 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.434 | Insulin | active | 2025-02 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.437 | TZD Thiazolidinediones | active | 2025-05 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.438 | medications_T2DM | active | 2023-08 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.440 | relatedconditions_T2DM SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.442 | Blood Glucose | active | 2024-07 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.459 | Liver cancer | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.47 | ACE inhibitor allergy SCT | active | 2022-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.474 | Allergy to Tdap Vaccine | active | 2023-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.475 | Allergy to Td Vaccine | active | 2023-06 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.481 | medications_hypertension | active | 2024-12 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.492 | Inhaled Corticosteroids Allergy | active | 2023-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.498 | Metformin AllergyIntolerance SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.508 | Abdominal aortic imaging CPT | active | 2023-07 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.517 | Hemoglobin A1c | active | 2024-03 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.518 | Drug hypersensitivity I10 | active | 2023-07 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.519 | Drug hypersensitivity SCT | active | 2023-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.520 | Drug hypersensitivity | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.521 | Diabetic Kidney Disease I10 | active | 2023-07 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.523 | Diabetic kidney disease | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.524 | Chronic Hepatitis SCT | active | 2023-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.525 | Chronic Hepatitis | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.527 | OCS_Prednisone | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.531 | Anti IgE Medications | active | 2023-07 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.532 | IL5 Antagonists | active | 2023-07 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.533 | Mast cell stabilizers for asthma | active | 2023-07 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.534 | Vasospastic disease I10 | active | 2023-08 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.535 | Vasospastic disease SCT | active | 2023-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.536 | Vasospastic disease | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.537 | Hemiplegic and basilar migraine I10 | active | 2023-07 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.538 | Hemiplegic and basilar migraine SCT | active | 2023-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.539 | Hemiplegic and basilar migraine | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.540 | Peptic ulcer disease I10 | active | 2023-07 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.541 | Peptic ulcer disease SCT | active | 2023-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.542 | Peptic ulcer disease | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.544 | Bleeding disorder I10 | active | 2023-07 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.545 | Bleeding disorder SCT | active | 2023-07 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.548 | Electronic cigarettes or Vaping | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.549 | Bleeding disorder | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.552 | Triptans | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.553 | CGRP receptor antagonists | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.554 | Ditans | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.555 | Ergots | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.556 | Migraine specific NSAIDs | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.557 | OTC migraine analgesics | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.559 | medications_migraine_acute | active | 2023-11 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.560 | relatedconditions_migraine I10 | active | 2023-08 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.561 | conditions_migraine | active | 2023-08 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.562 | relatedconditions_migraine SCT | active | 2023-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.563 | relatedconditions_migraine | active | 2023-08 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.564 | Triptan Allergy Intolerance SCT | active | 2023-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.565 | Triptan Allergy Intolerance | active | 2025-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.566 | Ischemic bowel disease SCT | active | 2023-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.567 | Ischemic bowel disease I10 | active | 2023-08 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.568 | Ischemic bowel disease | active | 2023-08 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.573 | conditions_hyperlipidemia I10 | active | 2023-08 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.574 | conditions_hyperlipidemia SCT | active | 2023-08 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.575 | conditions_hyperlipidemia | active | 2023-08 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.578 | PIM_Schedule V | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.580 | PIM_Acarbose | active | 2023-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.582 | PIM_Dulaglutide | active | 2023-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.583 | PIM_Glimepiride | active | 2023-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.585 | PIM_Glucophage | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.587 | PIM_Glucovance | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.588 | Glyburide PIM | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.590 | Alpha glucosidase inhibitors | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.592 | Azotemia | active | 2023-08 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.594 | Intolerance to ARB SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.595 | ICS Low | active | 2024-12 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.596 | ICS Medium | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.597 | ICS High | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.598 | Low Dose ICS Formoterol | active | 2024-05 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.600 | PIM_Vitamin B12 Level_LOINC | active | 2023-09 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.601 | PIM_Vitamin B12 Level_CPT | active | 2023-09 | us | hl7 | cpt | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.604 | PIM_Glyburide | active | 2023-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.605 | PIM_Pioglitazone | active | 2023-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.606 | PIM_Semaglutide | active | 2023-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.607 | PIM_Linagliptin | active | 2023-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.609 | Macrolide_Azithromycin | active | 2023-08 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.61 | Secondary antihypertensives | active | 2023-07 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.610 | Long Acting Beta Agonists (LABA) Non_Formoterol | active | 2023-11 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.612 | Wolff Parkinson White SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.613 | Wolff Parkinson White I10 | active | 2023-09 | us | hl7 | icd | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.614 | Wolff Parkinson White | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.615 | medications_Asthma | active | 2024-12 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.619 | ICS_LABA_LAMA | active | 2023-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.620 | Low Dose ICS_LABA_Non Formoterol | active | 2024-06 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.621 | Medium ICS_LABA Non Formoterol | active | 2023-11 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.623 | LAMA Allergy SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.624 | LABA Allergy SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.625 | BetaBlock NonCS Secondary Allergy SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.626 | Eplerenone Allergy SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.627 | Spironolactone Allergy SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.628 | SGLT2 Inhibitors Allergy SCT | active | 2024-04 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.629 | PIM_Refill_Request_Antilipemics_LFTs | active | 2023-09 | us | hl7 | loinc | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.630 | Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.631 | Pneumococcal Vaccine Allergy SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.632 | Meglitinides Allergy SCT | active | 2024-04 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.633 | DPP4i Allergy SCT | active | 2024-04 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.635 | Alpha_glucosidase inhibitors allergy SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.636 | Glucagon_Like Peptide 1 Receptor Agonist (GLP1RA) Allergy SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.637 | Insulins Allergy SCT | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.638 | TZD Allergy SCT | active | 2024-04 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.639 | T2DM_Medications Allergy SCT | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.642 | T2DM_Medications Allergy RXNORM | active | 2023-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.643 | T2DM_Medications Allergy SNOMED | active | 2023-09 | us | hl7 | sct | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.646 | T2DM_Medication Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.647 | Statins Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.649 | ACE Inhibitors Allergy Intolerance | active | 2025-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.650 | ARB Allergy Intolerance | active | 2025-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.652 | Long Acting Muscarinic Antagonists (LAMA) Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.653 | Long Acting Beta Agonists (LABA) Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.654 | BetaBlocker NonCS Secondary Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.656 | MRA Allergy Intolerance | active | 2025-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.657 | Eplerenone Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.658 | Spironolactone Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.659 | SGLT2i Allergy Intolerance | active | 2025-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.660 | Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.661 | Tetanus, Diphtheria, Pertusis (Tdap) Vaccine Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.665 | Tetanus toxoid, diphtheria (Td) Vaccine Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.666 | Human Papillomavirus (HPV) vaccine Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.667 | Herpes Zoster Vaccine Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.670 | Pneumococcal Vaccine Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.671 | Inhaled Corticosteroids(ICS) Allergy Intolerance | active | 2023-09 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.672 | LABA(Formoterol only) | active | 2023-11 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.674 | PIM_Tirzepatide | active | 2023-09 | us | hl7 | rx | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.675 | GLP1RA Allergy Intolerance | active | 2025-04 | us | hl7 | vsac | ||
us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.676 | PIM_Diabetes_Testing_Supplies | active | 2025-05 | us | hl7 | cms |